Applied Genetic Technologies Corporation Культура компании

Ms. Susan B. Washer, also known as Sue, has been the President and Chief Executive Officer of Applied Genetic Technologies Corporation since March 2002. Ms. Washer is an experienced entrepreneur with a strong scientific and operational background. She has 10 years of pharmaceutical management and research experience. She also served at Abbott Labs and Eli Lilly as well as 11 years of senior management experience at entrepreneurial firms in the Gainesville area. She successfully raised over $15M at AGTC in their second round of funding in November of 2003. She served as the Chairman of the Board of Directors at BioFlorida. She serves as a Director of Alliance at Regenerative Medicine. She has been a Director of Applied Genetic Technologies, Corporation since November 2003. She serves as a Director of BioFlorida. She is a member of the Executive Committee at UF's Center for Entrepreneurship and Southeast BIO; and a Board Member at the Gainesville Area Chamber of Commerce and the Florida High Tech Corridor Council. Ms. Washer has a B.S. in biochemistry from Michigan State University and an MBA from the University of Florida where she was one of the first graduates from the Business School's Entrepreneurship program.

Mr. Stephen W. Potter, also known as Steve, MBA, has been Chief Business Officer at Applied Genetic Technologies Corporation since January 2015 and served as its Vice President since January 2015 until August 29, 2017. Mr. Potter served as an Executive Vice President of Neostem, Inc. since July 15, 2013. He served as Senior Vice President of Operations and Corporate Development at Osiris Therapeutics, Inc. from February 2011 to November 16, 2012. During Mr. Potter's tenure at Osiris, he worked as a member of the senior leadership that achieved approval of the first-ever stem cell drug therapy, Prochymal(R). He was responsible for the launch and overall management of the Bio-Surgery business unit and had operational oversight for multiple functional areas including manufacturing, human resources, IT, legal and business development. He has more than 20 years of life science management experience as Senior Vice President of Corporate and Business Development at Genzyme Corporation. He served as Vice President of Corporate and Business Development at Genzyme Corporation from 2000 to 2006. During his more than ten years at Genzyme, Mr. Potter led a team responsible for providing strategic and transactional direction to Genzyme's business units. He served as Senior Vice President of Business Development for DuPont's Pharmaceutical subsidiary in Wilmington, Delaware. Mr. Potter was a Principal at Booz, Allen & Hamilton in the Life Sciences Practice. Mr. Potter is a seasoned senior executive with extensive management experience at biotechnology and pharmaceutical companies. He has also held positions at DuPont Pharmaceuticals, E.I. Dupont de Nemours and Company, Inc., and Booz Allen & Hamilton. He served as a Director of Neostem, Inc., from February 11, 2011 to July 15, 2013. Mr. Potter graduated from the Harvard Business School in 1989 with an MBA in General Management. He earned a BS in Economics from the University of Massachusetts in 1979.

Dr. William W. Hauswirth, Ph.D., Co-Founded Applied Genetic Technologies Corporation in 1999. Dr. Hauswirth serves as a Member of Scientific Advisory Board at Applied Genetic Technologies, Corporation. Dr. Hauswirth served as Secretary of Applied Genetic Technologies Corporation. After an NIH Fellowship in the Biochemistry Department at Johns Hopkins University, he joined that department as an Assistant Professor. In 1976, Dr. Hauswirth joined the faculty at the University of Florida College of Medicine. Dr. Hauswirth is, in part, responsible for determining the mechanism of replication of AAV DNA, the discovery of mitochondrial DNA heteroplasmy in mammals, and the first successful ribozyme-mediated rescue of a dominant genetic disease in animals (Retinitis Pigmentosa model in rats). His current interests involve three areas: 1. In vitro and in vivo definition of DNA elements regulating photoreceptor cell-specific expression. 2. Development of viral vectors for efficient and specific delivery of genes to the photoreceptor cell in animals. 3. Delivery and testing of potentially therapeutic genes for Retinitis Pigmentosa and Macular Degeneration in natural and transgenic animal models of human disease. These projects are currently funded by multiple NIH and foundation grants. Hauswirth is inventor or co-inventor on patent applications involving methods for obtaining AAV-mediated gene delivery specifically to retinal photoreceptor cells and to retinal pigmented epithelial cells, for AAV-mediated ribozyme therapy against autosomal dominant ocular disease, and for functional genomics using AAV delivered ribozymes. Dr. Hauswirth received his B.S. in Chemistry from Stanford University and his PhD from Oregon State University in Physical Chemistry.

Dr. Nicholas Muzyczka, Ph.D., also known as Nick, Co-Founded Applied Genetic Technologies Corporation in 1999. As a fellow in Dan Nathans laboratory, Dr. Muzyczka designed some of the earliest mammalian vectors based on SV40 virus. He subsequently developed the first AAV vectors and has been a leader in the development of this vector technology. He has contributed both to the study of the basic biology of AAV, as well as its application to human diseases. His laboratory is currently the leader in studies of the biochemistry of AAV transcription, DNA replication, and packaging. He is also a leader in the use of AAV vectors for central nervous system therapy. Dr. Muzyczka served as a Director at Applied Genetic Technologies Corporation. Dr. Muzyczka received his B.S. in Biology at Antioch College and his Ph.D. in Biochemistry at Johns Hopkins University.

Mr. William A. Sullivan, also known as Bill, has been Chief Financial Officer of Applied Genetic Technologies Corporation since August 2, 2017. Mr. Sullivan served as Principal Accounting Officer at Merrimack Pharmaceuticals, Inc. until April 29, 2016 and served as its Treasurer since February 2010 until April 29, 2016. He served as Chief Financial Officer at Merrimack Pharmaceuticals, Inc. from May 2011 to August 11, 2015 and served as its Head of Finance and Accounting since August 11, 2015. He has more than 20 years of experience in corporate finance, leading strategic transactions, fundraising and accounting. He served as a Controller of Merrimack Pharmaceuticals, Inc., from November 2007 to February 2010 and its Vice President of Finance from February 2010 to May 2011. Mr. Sullivan headed up finance team at Merrimack and manages all of its day to day reporting, accounting, financial planning, procurement management and played the lead financial role in its investor relations. He has a diverse career which includes establishing and managing finance departments and working in public and private corporate accounting. Previously, he served as Corporate Controller of Vette Corp., from October 2004 to November 2007. Mr. Sullivan began his career at Arthur Andersen LLP, where he obtained his certified public accountant license. He is a Certified Public Accountant (CPA). He holds a Bachelor's Degree from Williams College, a Master's degree in Business Administration (MBA) and a Master's degree in Accounting from Northeastern University's Graduate School of Professional Accounting.

Dr. Terence R. Flotte, also known as Terry, M.D., serves as Scientific Advisor of The Alpha-1 Project, Inc. Dr. Flotte co-founded Applied Genetic Technologies Corporation in 1999. Dr. Flotte serves as Dean of the School of Medicine, Provost and Executive Deputy Chancellor of the University of Massachusetts Medical School (UMMS). Dr. Flotte serves UMMS as Chief Academic and Administrative Officer of the School of Medicine, overseeing all academic activities of the basic and clinical science departments, including education and research for the School of Medicine and the Graduate School of Biomedical Sciences. He joined the Medical School in May 2007 from the University of Florida, where he was the Nemours Eminent Scholar and Chair of the Department of Pediatrics for the College of Medicine. In 1996, he joined the faculty of the University of Florida and was appointed Associate Director of UF's Powell Gene Therapy Center. Since 2000, he served as Director of the Powell Center and founding Director of the newly established UF Genetics Institute, a cross-campus multidisciplinary unit encompassing gene therapy, human genetics, agricultural genetics and comparative genomics. In 2002, he stepped down from these roles to accept the position of Chair of the Department of Pediatrics. As UF Pediatrics Chair, he led the department in a number of key projects, including the establishment of a Division of Cellular and Molecular Therapy that has garnered more than $2 million per year in extramural funding from the National Institutes of Health and the creation of the Congenital Heart Disease Center of Excellence, which combines cutting-edge clinical care from pediatric cardiac surgery and cardiology in a unique single-line-of-business entity. Under his stewardship, the research grant revenue to the Department of Pediatrics nearly doubled and clinical revenue increased by nearly 50 percent. An internationally known pioneer in human gene therapy, he investigates the use of gene therapy for genetic diseases that affect children, mainly cystic fibrosis. In 1995, Dr. Flotte and his colleagues became the first to use the apparently harmless adeno-associated virus, or AAV, as a vehicle to deliver corrective genes to targeted sites in the body, including the damaged airways of adults with cystic fibrosis. Since joining UF, he has continued his pediatric practice. He serves as Scientific Advisory Board Member at Editas Medicine Inc. He has been a Scientific Advisor at Dimension Therapeutics, Inc. since April 2014. He serves as Member of Board of Trustees of UMass Memorial Medical Center, Inc. He serves as Trustee at UMass Memorial Health Care, Inc. Dr. Flotte is a member of the American Society for Gene Therapy and the American Society of Microbiology, among many other professional associations. He is the author of more than 180 scholarly papers and his research was funded by the National Institutes of Health, the Cystic Fibrosis Foundation and the Juvenile Diabetes Research Foundation. He has received numerous honors and awards including the Society for Pediatric Research's E. Mead Johnson Award for Outstanding Scientific Contributions and the University of Florida Faculty Research Prize in Clinical Science. He received his undergraduate degree in the biological sciences from the University of New Orleans in 1982 and his medical degree from the Louisiana State University School of Medicine in 1986. After serving his residency in pediatrics at Johns Hopkins University, he completed a pediatric pulmonary fellowship and postdoctoral training in molecular virology there in 1992.

Dr. Richard Jude Samulski, Ph.D., serves as the President of Chatham Therapeutics LLC. Dr. Samulski has been Executive Chairman and Chief Scientific Officer at Bamboo Therapeutics, Inc. since December 2014 and serves as its Scientific Founder. Dr. Samulski has been Vice President of Gene Therapy of Bamboo Therapeutics, Inc. since August 29, 2016. He serves as Scientific Advisor at Calimmune, Inc. Dr. Samulski has been Scientific Co-Founder of Asklepios Biopharmaceutical, Inc. since 2003 and served as its Chief Executive Officer. In 1993, Dr. Samulski co-founded an AAV-based gene therapy company Merlin. He also co-founded Applied Genetic Technologies Corporation in 1999. He also serves as a gene therapy consultant to the FDA. Through the UNC gene therapy center, Dr. Samulski has produced within an academic setting an FDA approved AAV clinical vector used to treat children with the neurological disorder of Canavan's disease. Dr. Samulski served at AAV for 25 years. He served as President of American Society of Gene and Cell Therapy. Dr. Samulski has been Director of the University of North Carolina Gene Therapy Center for eight years. He serves as a Member of Scientific Advisory Board of Ceregene, Inc. He serves as a Director of Bamboo Therapeutics, Inc. He served at AAV biology as a Member of the scientific advisory board of Avigen, a new AAV research company. Dr. Samulski has over 20 patents filed or issued in the area of AAV vectors. Dr. Samulski served as a Member of the Recombinant DNA Advisory Committee (RAC), a committee tasked with assisting the FDA with approving or disapproving gene therapy clinical trials in the United States. He serves as Professor of Pharmacology of The University of North Carolina. Dr. Samulski is a recipient of the President's Distinguished Research Award from the University of Pittsburgh. He completed Post-Doctoral training at Princeton. Dr. Samulski's graduate work (1978-82) demonstrated the first use of AAV as a viral vector and culminated in the first US patent involving non-AAV genes inserted into AAV. Dr. Samulski received his PhD in Medical Microbiology and Immunology from the University of Florida and his research focuses on the study of the dependent parvovirus adeno-associated virus (AAV).

Dr. Barry J. Byrne, M.D., Ph.D. is Founder of AGTC. Dr. Byrne serves as Director of Rare Disease Research, Therapy Professor of Molecular, Pediatrics, Genetics & Microbiology and Associate Chairman of Pediatrics, Department of Pediatrics/Powell Gene Therapy Center at University of Florida Powell Center. Dr. Byrne serves as an Earl and Christy Powell University Chairman of Genetics. He is the Founding Editor of Human Gene Therapy, Clinical Development. Dr. Byrne is physician-scientist trained as a cardiologist and molecular virologist. He joined the University of Florida in 1997. He served at James Scholar the University of Illinois. At Hopkins, Dr. Byrne directed the cardiomyopathy and transplantation program and worked on gene discovery related to myocardial cell structure and development. He worked on vector technology and led to important discoveries on the purification and production of AAV. Dr. Byrne co-Founded Applied Genetic Technologies Corporation in 1999. He serves as a Director of UF Powell Gene Therapy Center and ASGCT. He serves as a Member of Scientific Advisory Board of Capricor Therapeutics, Inc. He serves as a Member of Scientific Advisory Board of U.S. Stem Cell, Inc. He serves as a Member of Scientific and Clinical Advisory Board at Audentes Therapeutics, Inc. He serves as a Member of the Editorial Board of Plos ONE. Dr. Byrne served as a Member of Scientific Advisory Board at Abeona Therapeutics Inc. until June 29, 2016. Dr. Byrne served as a Member of Scientific Advisory Board at Amicus Therapeutics, Inc. He served as a Member of Scientific Advisory Board at Bioheart, Inc. He trained in Pediatrics and Cardiology at Johns Hopkins University. Dr. Byrne is a clinician scientist and studied a variety of rare diseases with specific attention to develop therapies for inherited muscle disease. He is a pediatric cardiologist and focused on conditions that lead to skeletal muscle weakness and problems in heart and respiratory function. His group has made significant contributions to the understanding and treatment of Pompe disease. He has B.S. degree from Denison University, M.D. and Ph.D. from the University of Illinois and completed Pediatrics residency, cardiology fellowship training. He has Post-Doctoral Training in Biological Chemistry at the Johns Hopkins Hospital.

Dr. Matthew Feinsod, M.D., has been Interim Chief Medical Officer of Applied Genetic Technologies Corporation since September 5, 2017 and served as its Product Development Office. Dr. Feinsod Co-founded and served as the Chief Medical Officer of Imagen Biotech, Inc. Dr. Feinsod served as Senior Vice President of Strategy & Product Development at Eyetech Pharmaceuticals where he spent five years in a variety of functions helping to develop and launch Macugen and an anti-PDGF aptamer now in Phase 3 clinical trials with Ophthotech. Prior to joining Eyetech, Dr. Feinsod served as a Medical Officer for the FDA Division of Anti-inflammatory, Analgesic and Ophthalmologic Drug Products, where he was a primary reviewer for both IND and NDA ophthalmology regulatory applications. Concurrently, he held a clinical trials/drug development fellowship position in George Washington University's Department of Ophthalmology and served on the University hospital's Institutional Review Board. Previously, Dr. Feinsod conducted post-doctoral molecular biology research with a focus on nucleotide science at Cornell University Medical Center. Dr. Feinsod is a board-certified ophthalmologist with extensive corporate and regulatory expertise in the development of novel therapies for ophthalmic diseases. In his previous positions, he has played key roles in corporate finance, developing and implementing clinical and regulatory strategy, due diligence and licensing. Dr. Feinsod serves on the board of directors of World Eye Mission, a non-profit organization. He continues to practice ophthalmology on a part-time basis. Dr. Feinsod holds several patents in the field of ophthalmology and in emitted light-stabilization. He received his undergraduate degree from the Wharton School of Business and his MD from the George Washington University School of Medicine and completed his residency at the Manhattan Eye, Ear and Throat Hospital.